[SR-Users] Phase III clinical trials of Kamailio DMQ

Daniel-Constantin Mierla miconda at gmail.com
Thu Apr 1 18:16:19 CEST 2021

On 01.04.21 06:34, Alex Balashov wrote:
> For immediate release:
> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
> with
> Posner | Palner Pharmaceuticals, are pleased to announce the eagerly
> anticipated start of Phase III clinical trials of Kamailio DMQ module
> replication.
> In this stage of the investigation of the promising replication
> scheme, which
> was developed in record time, DMQ will be tested in a rigourous,
> double-blind,
> controlled CI/CD process for large-scale efficacy and continually
> monitored for
> safety in shorter and longer terms.
> The now-concluded second phase established basic safety and Phase 2b
> entailed a
> dose-finding study for the optimal number of batched `dmq_usrloc`
> contacts per
> kilogram of cloud computing resource.
> The main cohort of the main sequence of the Phase III trial will
> enroll 380
> randomly selected, statistically representative Floridian SIP
> registrars and
> 5700 SIP dialogs, also in the state of Florida. When asked about the
> disparity
> in the number of registrars versus dialogs, Alex Balashov of Evariste
> said, "It
> is reflective of the small number of SIP registrars in Florida; not to be
> indelicate, but consider the median age of the population."
> As previously remarked upon in proceedings of the World SIP
> Organisation (WSO),
> the choice of Florida as a venue attracted some questions. We asked
> Fred Posner
> of Posner | Palner about the clinical background informing this choice of
> replication study cohort:
> "Florida is a good place to find eventual consistency failures; the open
> climate and reluctance to accept traditional data integrity science
> would have
> sealed the deal, but when people started to drink bleach here, I saw an
> opportunity."
> Evariste and Posner | Palner are aiming for a US Food & Drug
> Administration EUA
> (Emergency Use Authorisation) for DMQ replication as a prophylactic data
> redundancy and failover measure to ward off the development of
> moderate to
> severe viral Sonus Haemorrhagic Fever symptoms.
> Phase II studies have painted a promising a picture of the DMQ
> architecture's
> ability to reduce moderate to severe symptoms and associated 28-day
> mortality
> by more than 90%, albeit over a small sample size and in enterprise
> patients
> with known pre-existing comorbidities such as Session Border
> Controller and
> BroadSoft Multi-System Inflammatory Syndrome.  Phase III trials seek
> to bolster
> quantums of broader efficacy, including efficacy for localised
> outbreaks of
> small to medium business softswitch.
> Of the control group, Balashov said, "They will receive a standard
> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
> confirmation
> messages. We proudly developed this approach in early 2020 in
> consultation with
> the highest levels of the Trump presidential administration; it is called
> TENP, or 'The Emperor's New Potion.' It is a successor to that
> administration's
> previous approved placebo protocol, SHTI - Small Hands, Tremendous
> Initiatives."
> Despite speculative autism and packet fragmentation claims by Florida
> Governor
> Ron DeSantis, Balashov was quick to provide reassurance about side
> effects from
> DMQ in the Phase III trial.
> "The incidence of severe allergies to plain-text UDP was within standard
> deviation over the mean for all insecure replication, and there's
> support for
> other transports on the way. Anyway, we have a robust adverse effects
> reporting
> system in our issue tracker and solid surveillance. Don't let partisan
> politics
> dissuade you from allowing request lines with the KDMQ method."
> Other industry sources have reported that DMQ is not the only replication
> investigation undertaken by Evariste and Posner | Palner, although it
> is the only
> prophylactic suitable for the early infection development and
> inflammatory
> phases of a broad class of SBC-complex syndromes typically afflicting
> service
> providers. A recent IETF preprint by the same authors has shown
> high-quality
> preliminary data suggesting statistically significant improvement in
> morbidity
> outcomes from Perimeta and Nokia via a later-stage therapeutic
> intervention
> with a monoclonal, monorepo Github cocktail administered intravenously.

Is it based on the bleeding-edge-proxy mSNA technology?

Does it do the microchip implant to the VoIP administrators or to the


   * mSNA: messenger SipoNucleic Action


Daniel-Constantin Mierla -- www.asipto.com
www.twitter.com/miconda -- www.linkedin.com/in/miconda
Funding: https://www.paypal.me/dcmierla

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.kamailio.org/pipermail/sr-users/attachments/20210401/7e7d98c2/attachment.htm>

More information about the sr-users mailing list